Research programme: hepatitis C therapies - Merck

Drug Profile

Research programme: hepatitis C therapies - Merck

Alternative Names: HCV NS5A inhibitors - Idenix; IDX 19368; IDX 316; IDX-136; IDX-20963; IDX077; IDX102; IDX791; IDXSCA; IDXSCB; NV 08; NV 08B; Uridine nucleoside - Idenix; Uridine nucleotide analog - Idenix; Uridine nucleotide prodrug - Idenix

Latest Information Update: 25 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Idenix Pharmaceuticals; University of Cagliari
  • Developer Merck & Co
  • Class Macrocyclic compounds; Nucleosides
  • Mechanism of Action Hepatitis C protease inhibitors; Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus replication inhibitors; Polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatitis C

Most Recent Events

  • 07 Apr 2014 Idenix discontinues the development of IDX 20963
  • 20 Jun 2013 The US FDA places a hold on the initiation of clinical trials for IDX 20963 in Hepatitis C
  • 04 Feb 2013 Idenix discontinues its development of IDX 19368 following a communication with the US FDA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top